Clinical Trials on Primary Myelofibrosis in New Zealand

Total 8335 results

Celgene

Recruiting

Connect® Myeloid Disease Registry

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Primary Myelofibrosis

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)

Myelofibrosis

Belgium, Colombia, Canada, Italy, Spain, Austria, Germany, Czechia, Thailand, Hungary, Greece, Argentina, Brazil, Israel, Russian Federation, Mexico, Portugal, South Africa, Tunisia, Slovakia, Saudi Arabia, Poland, Algeria, Ireland, Mor...
MedImmune LLC

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects

Renal Insufficiency

New Zealand, Germany
Kartos Therapeutics, Inc.

Recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis

United States, France, Australia, Spain, Germany, Bulgaria, Israel, Italy, Poland
Syntara
Parexel

Recruiting

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Myelofibrosis

Taiwan, Australia, Korea, Republic of, United States
Austin Health

Terminated

Bicarbonate in Cardiac Surgery

Acute Kidney Injury

New Zealand, Australia
Celgene

Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Beta-thalassemia | Myelodysplastic Syndromes (MDS) | Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

United States, Japan, United Kingdom, Turkey, Greece, France, Australia, Belgium, Bulgaria, Canada, Germany, Israel, Italy, Malaysia, Spain, Sweden, Taiwan, Thailand, Tunisia, Lebanon, China, Netherlands
GT Urological, LLC

Completed

Clinical Investigation of GT UrologIcal, LLC's Artificial Urinary Sphincter (RELIEF II) (RELIEFII)

Male Stress Urinary Incontinence

Australia, Czechia, New Zealand
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Hematologic Malignancies | Myeloid Metaplasia

United States
Monash Medical Centre
Monash University; University of Auckland, New Zealand; Hudson Institute of Medical... and other collaborators

Recruiting

Anakinra for Preterm Infants Pilot

Inflammation | Prematurity; Extreme

Australia, New Zealand
GlaxoSmithKline

Completed

An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine

Migraine | Migraine Disorders

Australia, New Zealand
University of Auckland, New Zealand
Counties Manukau Health; Auckland Medical Research Foundation; Auckland District... and other collaborators

Unknown

Cyclophosphamide in Lupus Nephritis

Systemic Lupus Erythematosus

New Zealand
Memorial Sloan Kettering Cancer Center
Novartis

Terminated

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Myeloproliferative Neoplasms

United States
Zenflow, Inc.

Unknown

The Zenflow Spring System Feasibility and Safety Study (ZEST)

Benign Prostatic Hyperplasia

Bulgaria, New Zealand
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Renal Impairment

United States, New Zealand
Gilead Sciences

Completed

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Nonalcoholic Steatohepatitis (NASH) | Primary Sclerosing Cholangitis (PSC)

United States, New Zealand
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Canada, Australia, New Zealand, Singapore
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Zenflow, Inc.

Recruiting

The Zenflow Spring System EU Safety and Performance Study (ZEST EU)

Benign Prostatic Hyperplasia

Australia, New Zealand
Trigemina, Inc

Completed

TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine

High Frequency Episodic Migraine and Chronic Migraine

Chile, New Zealand, Australia
CSL Limited

Completed

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Primary Immune Deficiency

Australia, New Zealand
Arthrosi Therapeutics
Iqvia Pty Ltd

Completed

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

Renal Impairment

United States, New Zealand
Antisoma Research

Completed

Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma

Metastatic Renal Cell Carcinoma | Metastatic Malignant Melanoma

United Kingdom, New Zealand
Resurge Therapeutics Inc.

Recruiting

RT-310 Dose Escalation BPH Study

Lower Urinary Tract Symptoms | BPH (Benign Prostatic Hyperplasia)

New Zealand, Australia
Alessa Therapeutics Inc.

Completed

A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer (Biolen-PC)

Lower Urinary Tract Symptoms | Prostate Adenocarcinoma

United States, Australia, New Zealand
Light Sciences Oncology

Completed

Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

New Zealand, Australia
Novartis Pharmaceuticals

Terminated

A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocytopenia

United States
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
Danish Headache Center

Completed

Deep Phenotyping of Rosacea and Migraine

Migraine | Rosacea

Denmark
Danish Headache Center

Recruiting

Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine (SLIM)

Headache | Migraine Without Aura

Denmark
Danish Headache Center

Recruiting

Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM) (ILIM)

Headache | Migraine Without Aura

Denmark
Murdoch Childrens Research Institute
Royal Children's Hospital

Completed

What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?

Primary Immunodeficiency | Invasive Pneumococcal Disease, Protection Against | Invasive Pneumococcal Disease, Recurrent Isolated, 1 | Invasive Pneumococcal Disease, Recurrent Isolated, 2

Australia, New Zealand
CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
National Cancer Institute (NCI)

Completed

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States, Canada, New Zealand
Biosense Webster, Inc.

Completed

RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157 (RENABLATE-II)

Hypertension, Renal

Czech Republic, Italy, New Zealand, Spain
National Medical Research Council (NMRC), Singapore

Completed

Tamoxifen in Treating Patients With Primary Liver Cancer

Liver Cancer

New Zealand, Hong Kong, Indonesia, Malaysia, Pakistan, Singapore
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

New Zealand, Korea, Republic of, Italy
Trans Tasman Radiation Oncology Group

Completed

Feasibility of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer (BOLART)

Bladder Cancer

Australia, New Zealand
Intellia Therapeutics

Enrolling by invitation

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

Hereditary Angioedema

France, New Zealand, United Kingdom, Netherlands
Marina Kremyanskaya

Recruiting

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Essential Thrombocythemia | Myelofibrosis | MPN

United States
Gilead Sciences

Completed

Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function

Inflammatory Disease

United States, New Zealand, Germany
Noxopharm Limited

Completed

Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer

Cancer

New Zealand, Georgia, Australia
Valencia Technologies Corporation

Completed

eCoin for OAB Feasibility Follow-on Study

Overactive Bladder | Urge Incontinence | Urinary Urge Incontinence | Incontinence, Urinary

United States, New Zealand
Apellis Pharmaceuticals, Inc.

Completed

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. (PADDOCK)

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Thailand, New Zealand, Malaysia
Murdoch Childrens Research Institute
Royal Children's Hospital

Recruiting

Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children (CHOICE UTI)

Infection | Pediatric Infectious Disease | Complicated Urinary Tract Infection

Australia, New Zealand
Valencia Technologies Corporation

Completed

eCoin Tibial Nerve Stimulation for OAB

Urgency Urinary Incontinence

United States, New Zealand
Holbaek Sygehus

Enrolling by invitation

Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment (PRESERVE)

End Stage Renal Disease | Peritoneal Dialysis Complication

Denmark
Escient Pharmaceuticals, Inc
Novotech (Australia) Pty Limited

Completed

Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus

Pruritus | Cholestasis | Kidney Failure

Australia, New Zealand
InnoCon Medical
Odense University Hospital; Aarhus University Hospital; Herlev Hospital

Completed

Safety and Performance of UCon for the Treatment of the Symptoms of Overactive Bladder (OAB) / Bowel Dysfunction (BD)

Urinary Incontinence | Fecal Incontinence | Urge Incontinence | Urinary Incontinence, Urge | Nocturia | Urinary Frequency More Than Once at Night | Incontinence, Nighttime Urinary | Bowel Disorders Functional

Denmark
Incyte Corporation

Completed

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

MPN (Myeloproliferative Neoplasms)

United States

Clinical Trials on Primary Myelofibrosis in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations